Bristol-Myers Squibb Meets 80-Plus Relative Strength Rating BenchmarkInvestors Business Daily • 11/27/19
Why I'm Holding On to My Bristol-Myers Squibb Shares Now That the Celgene Acquisition Has ClosedThe Motley Fool • 11/24/19
Bristol-Myers stock slides premarket after melanoma trial fails to meet main goalMarket Watch • 11/20/19
FTC makes Celgene's Otezla divestiture official condition for Bristol-Myers acquisitionMarket Watch • 11/15/19
Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close WednesdayInvestors Business Daily • 11/15/19
Bristol-Myers Squibb wins antitrust approval to buy Celgene on condition it sell psoriasis drugReuters • 11/15/19
What’s Bristol-Myers Squibb’s Fair Stock Price Estimate Based On Expected 2019 Earnings?Forbes • 11/15/19
Why Celgene's Latest FDA Approval Makes Bristol-Myers Squibb's Dividend Look Even BetterThe Motley Fool • 11/12/19